drugset / Trial / NCT02129647

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

NCT02129647

Phase 2 Completed 13 enrolled NYU Langone Health
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the study drug, AXITINIB, has any effect on tumors found in patients with Neurofibromatosis Type 2 (NF2).

Timeline

Start
2014-04
Primary completion
2019-02-05
Completion
2019-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Axitinib Small molecule 10 mg Oral